BioPharmSignal logoBioPharmSignal

Biotech News

OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review

OraSure Technologies, Inc. (OSUR)OraSure Technologies, Inc.2026-06-25 13:46 ESTFDA / regulatory

BETHLEHEM, Pa., Jan. 05, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) (“OraSure” and “OTI”), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that it submitted two separate applications at the end of 2025 to the U.S.

Open original release

Related news

OSUROraSure Technologies, Inc.2026-06-25 13:46 EST

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OSUROraSure Technologies, Inc.2026-06-25 13:46 EST

OraSure Announces First Quarter 2026 Financial Results

OSUROraSure Technologies, Inc.2026-06-25 13:46 EST

OraSure to Participate in Upcoming Investor Conference

OSUROraSure Technologies, Inc.2026-06-25 13:46 EST

OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates

OSUROraSure Technologies, Inc.2026-06-25 13:46 EST

OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital

OSUROraSure Technologies, Inc.2026-06-25 13:46 EST

OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th

OSUROraSure Technologies, Inc.2026-06-25 13:46 EST

OraSure to Launch OraQuick™ HIV Self-Test in Canada

OSUROraSure Technologies, Inc.2026-06-25 13:46 EST

OraSure Announces Fourth Quarter 2025 Financial Results

OSUROraSure Technologies, Inc.2026-06-25 13:46 EST

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

OSUROraSure Technologies, Inc.2026-06-25 13:46 EST

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

View all latest news

OraSure Technologies, Inc.

OraSure Technologies is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

OSUROraSure Technologies, Inc.2026-06-26 09:31 EST

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OSUROraSure Technologies, Inc.2026-06-26 09:31 EST

OraSure Announces First Quarter 2026 Financial Results

OSUROraSure Technologies, Inc.2026-06-26 09:31 EST

OraSure to Participate in Upcoming Investor Conference

OSUROraSure Technologies, Inc.2026-06-26 09:31 EST

OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates

OSUROraSure Technologies, Inc.2026-06-26 09:31 EST

OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States